within Pharmacolibrary.Drugs.ATC.N;

model N05AB02_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.26,
    Cl             = 0.0008,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0004333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AB02_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fluphenazine is a typical antipsychotic drug of the phenothiazine class, primarily used to treat symptoms of schizophrenia and other psychotic disorders. It has been largely replaced by atypical antipsychotics in many settings but is still approved and used in some countries for psychosis management.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult patients after oral administration; scarce published data, so values approximate or from secondary sources.</p><h4>References</h4><ol><li><p>Correll, CU, et al., &amp; Saklad, SR (2021). Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. <i>CNS drugs</i> 35(1) 39–59. DOI:<a href=&quot;https://doi.org/10.1007/s40263-020-00779-5&quot;>10.1007/s40263-020-00779-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33507525/&quot;>https://pubmed.ncbi.nlm.nih.gov/33507525</a></p></li><li><p>Spanarello, S, &amp; La Ferla, T (2014). The pharmacokinetics of long-acting antipsychotic medications. <i>Current clinical pharmacology</i> 9(3) 310–317. DOI:<a href=&quot;https://doi.org/10.2174/15748847113089990051&quot;>10.2174/15748847113089990051</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23343447/&quot;>https://pubmed.ncbi.nlm.nih.gov/23343447</a></p></li><li><p>Højlund, M, &amp; Correll, CU (2023). Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. <i>Expert opinion on pharmacotherapy</i> 24(13) 1463–1489. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2023.2228686&quot;>10.1080/14656566.2023.2228686</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37345508/&quot;>https://pubmed.ncbi.nlm.nih.gov/37345508</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AB02_1;
